argenx SE/€ARGX
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About argenx SE
Argenx SE is a biotechnology company primarily engaged in the development of antibody-based therapies for the treatment of severe autoimmune diseases and cancer. The company leverages its proprietary SIMPLE Antibody™ platform to create differentiated immunology solutions. One of its flagship products is efgartigimod, designed to target the neonatal Fc receptor (FcRn) to modulate antibody levels, which has gained significant attention in therapeutic areas such as neuromuscular disorders. Founded in 2008, Argenx is headquartered in Ghent, Belgium, and has expanded its operations globally. The company's strategic positioning lies in its ability to combine deep insights into disease biology with cutting-edge technology to create novel treatments. Sources:
- Argenx Official Website: www.argenx.com
- "Argenx - Company Profile and News," Bloomberg, www.bloomberg.com
Ticker
€ARGX
Sector
Primary listing
BSE
Employees
1,599
Headquarters
Website
argenx SE Metrics
BasicAdvanced
€36B
36.44
€16.12
0.03
-
Price and volume
Market cap
€36B
Beta
0.03
52-week high
€658.00
52-week low
€456.30
Average daily volume
30K
Financial strength
Current ratio
5.595
Quick ratio
4.92
Long term debt to equity
0.583
Total debt to equity
0.708
Interest coverage (TTM)
142.45%
Profitability
EBITDA (TTM)
403.186
Gross margin (TTM)
52.15%
Net profit margin (TTM)
41.03%
Operating margin (TTM)
14.83%
Effective tax rate (TTM)
-92.89%
Revenue per employee (TTM)
€1,676,450
Management effectiveness
Return on assets (TTM)
4.83%
Return on equity (TTM)
24.72%
Valuation
Price to earnings (TTM)
36.444
Price to revenue (TTM)
13.283
Price to book
5.92
Price to tangible book (TTM)
6.14
Price to free cash flow (TTM)
134.279
Free cash flow yield (TTM)
0.74%
Free cash flow per share (TTM)
4.374
Growth
Revenue change (TTM)
88.04%
Earnings per share change (TTM)
-640.89%
3-year revenue growth (CAGR)
177.34%
10-year revenue growth (CAGR)
78.53%
3-year earnings per share growth (CAGR)
2.74%
10-year earnings per share growth (CAGR)
28.75%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for argenx SE stock?
argenx SE (ARGX) has a market cap of €36B as of August 26, 2025.
What is the P/E ratio for argenx SE stock?
The price to earnings (P/E) ratio for argenx SE (ARGX) stock is 36.44 as of August 26, 2025.
Does argenx SE stock pay dividends?
No, argenx SE (ARGX) stock does not pay dividends to its shareholders as of August 26, 2025.
When is the next argenx SE dividend payment date?
argenx SE (ARGX) stock does not pay dividends to its shareholders.
What is the beta indicator for argenx SE?
argenx SE (ARGX) has a beta rating of 0.03. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.